Finding weight loss strategies that work in primary care

Similar documents
Clinical Research on Lifestyle Interventions to Treat Obesity and Asthma in Primary Care Jun Ma, M.D., Ph.D.

The National Diabetes Prevention Program: An Update on Efforts in Michigan

Treating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group. Learning Objectives. Background. CAPA 2015 Annual Conference

Diabetes Prevention in Latinos

How To Prevent Type 2 Diabetes

TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.

Prevention of and the Screening for Diabetes Part I Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner January 19, 2012

Karen Kovach M.S, R.D Chief Scientific Officer Weight Watchers International Inc.

PATHWAYS TO TYPE 2 DIABETES. Vera Tsenkova, PhD Assistant Scientist Institute on Aging University of Wisconsin-Madison

The Link Between Obesity and Diabetes The Rapid Evolution and Positive Results of Bariatric Surgery

Behavioral Lifestyle Intervention in the Treatment of Obesity

Obesity in the United States Workforce. Findings from the National Health and Nutrition Examination Surveys (NHANES) III and

Understanding the Science of Type 2 Diabetes. Anne Westbrook and April Gardner NABT Dallas, TX November 1, 2012

Diabetes mellitus is a chronic condition that occurs as a result of problems with the production and/or action of insulin in the body.

Am I at Risk for type 2 Diabetes? Taking Steps to Lower the Risk of Getting Diabetes NATIONAL DIABETES INFORMATION CLEARINGHOUSE

DIET AND EXERCISE STRATEGIES FOR WEIGHT LOSS AND WEIGHT MAINTENANCE

WEIGHT MANAGEMENT PROGRAMS & RESOURCES

Adult Weight Management Training Summary

How To Understand And Understand The Concept Of Intermediate Hyperglycaemia

Antipsychotic Medications and the Risk of Diabetes and Cardiovascular Disease

ICUH Leveraging Technology to Deliver Culturally- Optimized Public Health Programs

Statins and Risk for Diabetes Mellitus. Background

General and Abdominal Adiposity and Risk of Death in Europe

Policy Feedback: Expanding access to prediabetes education

Diabetes is a. A case for prevention of type 2 diabetes mellitus

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY OBESITY CHRONIC CARE MODEL

Harmony Clinical Trial Medical Media Factsheet

Include Dietitian Services in Extended Health Care Plan

Lifestyle Insurance Interventions and the Cost of Diabetes Prevention

Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE - Diabetes

Sponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.

Nancy S. Swayze. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume V, A. Background

Optimizing Referral Systems to the Diabetes Prevention Program

ECONOMIC COSTS OF PHYSICAL INACTIVITY

嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯

Type 2 Diabetes Mellitus and Insulin resistance syndrome in Children

A starting point for today 30/04/2015. Obesity does matter. Obesity is modifiable. Reducing weight has demonstrable health benefit

How can nutrition education contribute to competency-based resident evaluation? 1 4

4/9/2015. Opportunities for Making Type 2 Diabetes Prevention a Reality. Pat Schumacher, MS, RD. Objectives

Supporting Diabetes Self-care in Underserved Populations: A Randomized Pilot Study Using. Medical Assistant Coaches

WICOMICO COUNTY LOCAL HEALTH IMPROVEMENT COALITION (LHIC) LOCAL HEALTH DIABETES ACTION PLAN

Managing obesity in primary care practice: a narrative review

The Influence of Infant Health on Adult Chronic Disease

Improving cardiometabolic health in Major Mental Illness

Double Diabetes: Definition, Diagnosis, Treatment, Prediction and Prevention.

Healthy People 2020 Spotlight on Health: Type 2 Diabetes Prevention. U.S. Department of Health and Human Services

Take a moment Confer with your neighbour And try to solve the following word picture puzzle slides.

Second- and Third-Line Approaches for Type 2 Diabetes Workgroup: Topic Brief

Understanding Diseases and Treatments with Canadian Real-world Evidence

Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Diabetes sections of the Guidelines)

Is Insulin Effecting Your Weight Loss and Your Health?

Metabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007

Chapter 5 DASH Your Way to Weight Loss

The Need for an Integrative Approach to Pediatric Obesity

BDA Work Ready Programme: Workplace health nutrition interventions aimed at improving individuals working lives

Technology Assessment

Insulin Receptor Substrate 1 (IRS1) Gene Variation Modifies Insulin Resistance Response to Weight-loss Diets in A Two-year Randomized Trial

4/4/2013. Mike Rizo, Pharm D, MBA, ABAAHP THE PHARMACIST OF THE FUTURE? METABOLIC SYNDROME AN INTEGRATIVE APPROACH

Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes

CME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus

Sedentarity and Exercise in the Canadian Population. Angelo Tremblay Division of kinesiology

Metabolic Syndrome with Prediabetic Factors Clinical Study Summary Concerning the Efficacy of the GC Control Natural Blood Sugar Support Supplement

New York State YMCA Diabetes Prevention Program: Outcomes and Implications. Academy of Medicine. October The New York.

Is surgery better? Jordan Kautz, MS IV A b atory are C erence, an UNC-CH School of Medicine

GRACE Team Care Integration of Primary Care with Geriatrics and Community-Based Social Services

Summary Evaluation of the Medicare Lifestyle Modification Program Demonstration and the Medicare Cardiac Rehabilitation Benefit

Weight Management in a Large, Integrated Health System: The Veterans Health Administration Experience

published online ,

Medical Fitness. Annual Meeting December By: Deb Riggs, MEd, General Manager

Treatment of Opioid Dependence: A Randomized Controlled Trial. Karen L. Sees, DO, Kevin L. Delucchi, PhD, Carmen Masson, PhD, Amy

A BS TR AC T. n engl j med 365;21 nejm.org november 24,

Evaluating the Implementation of a Primary Care Weight Management Toolkit

INSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT?

DCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study

Health System Strategies to Improve Chronic Disease Management and Prevention: What Works?

City of Houston Long-Range Financial Management Task Force Healthcare Benefits Questions

CASE B1. Newly Diagnosed T2DM in Patient with Prior MI

Diabetes and Obesity. The diabesity epidemic

Isagenix Clinical Research Summary Suk Cho, Ph.D., Eric Gumpricht, Ph.D., David Despain, M.Sc.

Primary Care Guidance Program: Non-Alcohol related Fatty Liver Disease (NAFLD) Guidance on Management in Primary Care

10/31/2014. Medication Adherence: Development of an EMR tool to monitor oral medication compliance. Conflict of Interest Disclosures.

Secure Messaging Evidence Table

Homeostatic Model Assessment (HOMA)

Dori M. Steinberg, PhD, MS, RD 310 Trent Drive Room 134, Trent Hall Box Durham, NC

Barriers to Healthcare Services for People with Mental Disorders. Cardiovascular disorders and diabetes in people with severe mental illness

Metabolic Syndrome Programs Designed to Lower Risks

Treatment for Severely Obese Patients

The first endoscopically-delivered device therapy for obese patients with type 2 diabetes

Proof of Concept Project for a Diabetes Prevention Service in Greater Manchester, United Kingdom

ESC/EASD Pocket Guidelines Diabetes, pre-diabetes and cardiovascular disease

The Burden Of Diabetes And The Promise Of Biomedical Research

Reversing type 2 diabetes: pancreas composition and function during return to normal glucose tolerance

February 26, Dear Mr. Slavitt:

THE IMPACT OF USING BLOOD SUGAR HOME MONITORING DEVICE TO CONTROL BLOOD SUGAR LEVEL IN DIABETIC PATIENTS

PROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain

TYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY. Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU

Proposed Data Collection Submitted for Public Comment and. AGENCY: Centers for Disease Control and Prevention (CDC),

Why is Diabetes Important To Your Company?

Diabetes Mellitus 1. Chapter 43. Diabetes Mellitus, Self-Assessment Questions

The Arguments: T2DM - tremendous economic burden globally Lifestyle / Pharm Rx:

Transcription:

Finding weight loss strategies that work in primary care Article: Wilson C. Obesity: Finding weight loss strategies that work in primary care. Nat Rev Endocrinol. 2013;9(3):126. Review: In this Research Highlights article, Carol Wilson, PhD, associate editor of Nature Reviews Endocrinology, comments on the results of 2 recent randomized, controlled trials that evaluated different weight loss strategies and their potential impact on primary care. 1 Dr Wilson first discusses the landmark Diabetes Prevention Program (DPP) study, which demonstrated the efficacy of lifestyle modifications for weight loss and reducing the risk of type 2 diabetes mellitus (T2DM). 2 The original DPP study, funded by the National Institutes of Health and supported by the Centers for Disease Control and Prevention, 2 included a total of 3234 nondiabetic participants from 27 clinical centers across the United States who were randomly assigned to 1 of 3 treatment groups: lifestyle intervention (intensive one-on-one intervention with a trained interventionist to address nutrition, exercise, and behavior modification); standard care (information on diet and exercise, but no intensive lifestyle intervention plus 850 mg of the glycemic control drug metformin twice daily); or standard care plus a placebo. All study participants were overweight and had impaired glucose tolerance (IGT), a well-recognized risk factor for developing T2DM. Each group s target goal was 5%-7% reduction in baseline body weight. After an average follow-up of 2.8 years, lifestyle intervention reduced the risk of progression to diabetes by 58% compared with 31% for patients who took metformin. 2 The incidence of diabetes was 11.0, 7.8, and 4.8 cases per 100 person-years in the placebo, metformin, and lifestyle groups, respectively. 2 Since the DPP results were published, lifestyle intervention has been incorporated into clinical guidelines for weight management and disease prevention. 3 Most recently, Ma and colleagues (Palo Alto Medical Foundation Research Institute, California) 3 set out to translate the findings from the DPP study to the primary care setting. Their study, the Evaluation of Lifestyle Interventions to Treat Elevated Cardiometabolic Risk in Primary Care (E- LITE) trial, was a randomized, controlled clinical trial in adults with overweight or obesity and prediabetes and/or metabolic syndrome enrolled from one primary care clinic. Participants were randomized to 1 of 3 arms: a coach-led, DPP-based lifestyle intervention (n=79); a self-directed, DVD-based lifestyle intervention (n=81); or usual care without information about weight loss or weight loss goals (n=81). The percentages of participants who achieved the 7% DPP-based weight-loss goal were assessed. During the 3-month intensive intervention phase of the study, the DPP-based behavioral weight-loss curriculum was delivered via either coach-led small groups or home-based DVD. 3 This was followed by a 12-month maintenance phase, in which lifestyle coaching and support were delivered remotely via an Internet resource (American Heart

Association Heart360 Web site for weight and physical activity goal setting and self-monitoring) and e-mail communications. After 15 months, the mean change in body mass index (BMI) from baseline was 2.2 in the coach-led group and 1.6 in the self-directed group versus 0.9 in the usual care group (P<0.001 and P=0.02, for the two DPP intervention arms, respectively). The predefined 7% DPP-based weight loss goal was met by 37% in the coach-led group (P=0.003), 36% in the self-directed group (P=0.004), and 14% in the usual care group. In addition, both interventions achieved greater net improvements in waist circumference and fasting plasma glucose level versus placebo. In her commentary, Dr Wilson indicates that the E-LITE study provides two empirically supported programs that can be readily adopted into routine [primary care] practice. 1,3 Figure 1 illustrates similar findings for the 5% and 10% weight-loss goal cut-points. Figure 1. Categorical weight loss at 6 and 15 months in the intention-to-treat population. Weight loss (A) less than or equal to baseline weight, (B) greater than or equal to 5% of baseline weight, (C) greater than or equal to 7% of baseline weight, and (D) greater than or equal to 10% of baseline weight. [Reprinted with permission from Ma J, Yank V, Xiao L, et al. Translating the Diabetes Prevention Program lifestyle intervention for weight loss into primary care: a randomized trial. JAMA Intern Med. 2013;173(2):113-121.]

The second study in Dr Wilson s commentary, published by Spring et al (Department of Preventive Medicine, Northwestern University, Chicago, Illinois), evaluated a mobile app-based weight loss strategy with potential for use in the primary care setting. 4 This 12-month study enrolled 69 adults with a BMI >25 and 40 from a Midwestern Veterans Affairs (VA) medical center outpatient clinic. Participants first completed a technology fluency assessment and received training on the use of a personal digital assistant (PDA) to record food intake, weight, and physical activity. They were then randomly assigned to either standard care or standard care supported by a PDA (+mobile group). Standard care consisted of the MOVE! group weight loss program, which is offered at all VA medical centers, and includes biweekly weight-loss sessions led by dietitians, psychologists, or physicians. 5 In addition to standard care, the +mobile group members were provided with PDAs, which they used to upload their daily diet and physical activity; they also received 10 15-minute coaching calls every 2 weeks for 6 months. An intent-to-treat analysis showed that participants assigned to the +mobile group lost a mean of 3.9 kg more weight (3.1% more weight loss relative to the control group) than those in the standard group at each post-baseline time point; there was no evidence that treatment effect varied across time. Figure 2 shows weight loss measured during specific time points. Compared with the standard group, the +mobile group had a significantly greater likelihood of achieving 5% weight loss from baseline at all time points: 36.7% for +mobile versus 0% for standard at 3 months; 41.4% versus 10.7% at 6 months; 33.3% versus 10.3% at 9 months; and 29.6% versus 14.8% at 12 months. 4 Participants in the +mobile group who were more adherent to the MOVE! program (evidenced by attending 80% of treatment sessions) lost significantly more weight than less adherent +mobile-group participants and either adherent or non-adherent standard group participants. Figure 2. Weight loss plotted over time for the connective mobile technology (+mobile) and standard groups. Weight loss was significantly greater for the +mobile group at 3, 6, and 9 months. [Reprinted with permission from Spring B, Duncan JM, Janke A, et al. Integrating technology into standard weight loss treatment: a randomized controlled trial. JAMA Intern Med. 2013;173(2):105-111.]

These findings indicate that mobile technology is a scalable, cost-effective means to augment the effectiveness of physician-directed weight loss treatment. 4 Data from other studies support the idea that intensive lifestyle interventions may not need to be performed in person to achieve meaningful weight loss. For example, Appel et al 6 demonstrated that telephone- and Internet-based treatment produced weight loss comparable to an in-person intervention among patients referred from primary care practices. Dr Wilson agrees with Spring et al 4 in that technology offers a very effective way to deliver components of weight loss treatment. 1 In conclusion, the randomized trials by Ma et al 3 and Spring et al 4 highlight the promise of effective weight loss strategies that can be readily adapted for the primary-care setting. Mobile technology offers a new way for clinicians and other health professionals to provide personalized components of behavioral weight loss treatment (ie, self-monitoring, goal setting, lifestyle counseling, and in-person sessions) at reduced cost and participant burden, thereby easing the strain on primary-care systems. 4

References 1. Wilson C. Obesity: finding weight loss strategies that work in primary care. Nat Rev Endocrinol. 2013;9(3):126. 2. Knowler WC, Barrett-Connor E, Sowler SE, et al; for the Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403. 3. Ma J, Yank V, Xiao L, et al. Translating the Diabetes Prevention Program lifestyle intervention for weight loss into primary care: a randomized trial. JAMA Intern Med. 2013;173(2):113-121. 4. Spring B, Duncan JM, Janke A, et al. Integrating technology into standard weight loss treatment: a randomized controlled trial. JAMA Intern Med. 2013;173(2):105-111. 5. Kinsinger LS, Jones KR, Kahwati L, et al. Design and dissemination of the MOVE! weightmanagement program for veterans. Prev Chronic Dis. 2009;6(3):A98. 6. Appel LJ, Clark JM, Yeh HC, et al. Comparative effectiveness of weight-loss interventions in clinical practice. N Engl J Med. 2011;365(21):1959-1968.